[go: up one dir, main page]

BR0211359A - Emprego de imidazotriazinonas substituìdas por 2-alcoxifenila - Google Patents

Emprego de imidazotriazinonas substituìdas por 2-alcoxifenila

Info

Publication number
BR0211359A
BR0211359A BR0211359-7A BR0211359A BR0211359A BR 0211359 A BR0211359 A BR 0211359A BR 0211359 A BR0211359 A BR 0211359A BR 0211359 A BR0211359 A BR 0211359A
Authority
BR
Brazil
Prior art keywords
disease
employment
alkoxyphenyl
substituted imidazotriazinones
phenylimidazotriazinones
Prior art date
Application number
BR0211359-7A
Other languages
English (en)
Inventor
Ulrich Niewoehner
Erwin Bischoff
Helmut Haning
Afssaneh Rahbar
Tiemo-Joerg Bandel
Wolfgang Barth
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of BR0211359A publication Critical patent/BR0211359A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

"EMPREGO DE IMIDAZOTRIAZINONAS SUBSTITUìDAS POR 2-ALCOXIFENILA". A presente invenção refere-se ao emprego de 2-fenil-imidazotriazinonas conhecidas, com radicais alquila curtos, não-ramificados na posição 9, e propriedades inibidoras de cGMP-PDE para preparação de medicamentos para tratamento de insuficiência cardíaca, psoríase, infertilidade feminina, câncer, diabete, doenças oculares como glaucoma, desordens do movimento estomacal, fibrose cística, dores prematuras de parto, pressão sang³ínea pulmonar elevada, doenças da bexiga, hiperplasia da próstata, tolerância induzida por nitrato, pré-eclâmpsia, alopecia, doença de Parkinson, dor, zumbido ou síndrome renal.
BR0211359-7A 2001-07-23 2002-07-17 Emprego de imidazotriazinonas substituìdas por 2-alcoxifenila BR0211359A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10135815A DE10135815A1 (de) 2001-07-23 2001-07-23 Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
PCT/EP2002/007959 WO2003011262A2 (de) 2001-07-23 2002-07-17 Verwendung von 2-alkoxyphenyl-substituierten imidazotriazinonen zur behandlung von erkrankungen, die im zusammenhang mit cgmp-regulierten vorgängen stehen

Publications (1)

Publication Number Publication Date
BR0211359A true BR0211359A (pt) 2004-07-13

Family

ID=7692784

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0211359-7A BR0211359A (pt) 2001-07-23 2002-07-17 Emprego de imidazotriazinonas substituìdas por 2-alcoxifenila

Country Status (28)

Country Link
US (3) US6930108B2 (pt)
EP (2) EP1474150B1 (pt)
JP (1) JP2005504751A (pt)
KR (1) KR20040032865A (pt)
CN (1) CN1649593A (pt)
AT (1) ATE442144T1 (pt)
AU (1) AU2002319296B2 (pt)
BG (1) BG108533A (pt)
BR (1) BR0211359A (pt)
CA (1) CA2454414A1 (pt)
CO (1) CO5560536A2 (pt)
CZ (1) CZ2004128A3 (pt)
DE (2) DE10135815A1 (pt)
EC (1) ECSP044956A (pt)
EE (1) EE200400056A (pt)
ES (1) ES2330418T3 (pt)
HR (1) HRP20040065A2 (pt)
HU (1) HUP0500734A3 (pt)
IL (1) IL159840A0 (pt)
MA (1) MA26128A1 (pt)
MX (1) MXPA04000675A (pt)
NO (1) NO20040294L (pt)
NZ (1) NZ530703A (pt)
PL (1) PL373392A1 (pt)
RU (1) RU2321406C9 (pt)
SK (1) SK442004A3 (pt)
UA (1) UA76997C2 (pt)
WO (1) WO2003011262A2 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10135815A1 (de) * 2001-07-23 2003-02-06 Bayer Ag Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
JP2006219374A (ja) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Ｐｄｅ７阻害作用を有するイミダゾトリアジノン誘導体
DE102004023069A1 (de) 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
DE102004038328A1 (de) * 2004-08-06 2006-03-16 Bayer Healthcare Ag Neue Verwendungen von 2-Phenyl-substituierten Imidazotriazinon-Derivaten
WO2006111495A1 (en) 2005-04-19 2006-10-26 Nycomed Gmbh Roflumilast for the treatment of pulmonary hypertension
CN102791701B (zh) * 2009-12-30 2014-02-12 深圳信立泰药业股份有限公司 作为二肽基肽酶iv(dpp-iv)抑制剂的3-(3-氨基哌啶-1-基)-5-氧代-1,2,4-三嗪衍生物
AT512084A1 (de) * 2011-10-20 2013-05-15 Univ Wien Tech Diazabicyclo- und diazaspiro-alkanderivate als phosphodiesterase-5 inhibitoren
EP3082428A4 (en) 2013-12-09 2017-08-02 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
US10131670B2 (en) * 2016-12-16 2018-11-20 Cystic Fibrosis Foundation Therapeutics, Inc. Bicyclic heteroaryl derivatives as CFTR potentiators
CN113461694A (zh) * 2021-08-05 2021-10-01 广东西捷药业有限公司 一种伐地那非类似物及其合成方法和应用
CN113583003A (zh) * 2021-08-05 2021-11-02 广东西捷药业有限公司 一种伐地那非类似物及其合成方法和应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE791025A (fr) 1971-11-19 1973-05-07 Allen & Hanburys Ltd Composes heterocycliques
GB1457873A (en) 1973-01-04 1976-12-08 Allen & Hanburys Ltd Imidazotriazines
DK109578A (da) * 1977-03-25 1978-09-26 Allen & Hanburys Ltd Fremgangsmaade til fremstilling af heterocycliske forbindelser
US4308384A (en) 1978-09-18 1981-12-29 Glaxo Group Limited Production of triazinones
US4479210A (en) * 1982-11-19 1984-10-23 U.S. Philips Corporation Record-disc player
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9114760D0 (en) * 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
PH31245A (en) * 1991-10-30 1998-06-18 Janssen Pharmaceutica Nv 1,3-Dihydro-2H-imidazoÄ4,5-BÜ-quinolin-2-one derivatives.
GB9301192D0 (en) * 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
US5602110A (en) * 1994-08-31 1997-02-11 Case Western Reserve University Method and composition for treating cystic fibrosis
US5656629A (en) * 1995-03-10 1997-08-12 Sanofi Winthrop, Inc. 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof
US6069156A (en) * 1995-04-10 2000-05-30 Fujisawa Pharmaceutical Co., Ltd. Indole derivatives as cGMP-PDE inhibitors
US6166219A (en) * 1995-12-28 2000-12-26 Fujisawa Pharmaceutical Co., Ltd. Benzimidazole derivatives
CA2238283C (en) * 1997-05-30 2002-08-20 Cell Pathways, Inc. Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions
DE19812462A1 (de) * 1998-03-23 1999-09-30 Bayer Ag 2-[2-Ethoxy-5(4-ethyl-piperazin-1-sulfonyl) -phenyl]-5-methyl-7-prophyl-3H-imidazo[5,1-f][1,2,4]triazin-4-on Dihydrochlorid
HRP20020585B1 (hr) * 1997-11-12 2013-02-28 Bayer Schering Pharma Aktiengesellschaft 2-fenil supstituirani imidazotriazinoni kao inhibitori fosfodiesteraze
JP4307719B2 (ja) * 1997-12-12 2009-08-05 セル パスウェイズ インコーポレイテッド 新形成治療用のｎ−ベンジル−３−インデニルアセトアミド誘導体
US6087368A (en) * 1998-06-08 2000-07-11 Bristol-Myers Squibb Company Quinazolinone inhibitors of cGMP phosphodiesterase
DE19827640A1 (de) 1998-06-20 1999-12-23 Bayer Ag 7-Alkyl- und Cycloalkyl-substituierte Imidazotriazinone
IL132406A0 (en) * 1998-10-21 2001-03-19 Pfizer Prod Inc Treatment of bph with cgmp elevators
US6225315B1 (en) * 1998-11-30 2001-05-01 Pfizer Inc Method of treating nitrate-induced tolerance
FR2792634B1 (fr) * 1999-04-20 2001-06-01 Synthelabo Derives de 2-alcoxy-cyclobutene-3,4-dione leur preparation et leur application en therapeutique
IL130968A (en) * 1999-07-15 2002-12-01 Shmuel Simon Pharmaceutical composition comprising sildenafil or its analogs, useful for the treatment of tinnitus and hearing loss
EP1218003A4 (en) * 1999-09-13 2004-02-11 David M Swope COMPOSITION AND METHOD FOR REDUCING NEUROLOGICAL SYMPTOMATOLOGY
DE19943815A1 (de) * 1999-09-14 2001-03-15 Merck Patent Gmbh Verwendung von Thienopyrimidinen
US6503908B1 (en) 1999-10-11 2003-01-07 Pfizer Inc Pharmaceutically active compounds
TWI265925B (en) * 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
ATE341329T1 (de) * 1999-10-12 2006-10-15 Lilly Icos Llc Arzneimittel zur behandlung von neuropathien
IL139073A0 (en) * 1999-10-21 2001-11-25 Pfizer Treatment of neuropathy
TW200400821A (en) 1999-11-02 2004-01-16 Pfizer Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient
GB0008694D0 (en) * 2000-04-07 2000-05-31 Novartis Ag Organic compounds
WO2001078781A2 (en) * 2000-04-19 2001-10-25 Johns Hopkins University Methods for prevention and treatment of gastrointestinal disorders
EP1278522B1 (en) * 2000-04-19 2006-10-25 Lilly Icos LLC Pde-v inhibitors for treatment of parkinson's disease
AU2001276607A1 (en) * 2000-08-11 2002-02-25 Pfizer Inc. Treatment of the insulin resistance syndrome with selective CGMP PDE5 inhibitors
BR0113644A (pt) * 2000-08-30 2003-07-29 Lilly Icos Llc Usos do inibidor de pde5 no tratamento de enxaqueca
GB0025782D0 (en) * 2000-10-20 2000-12-06 Pfizer Ltd Use of inhibitors
CA2436576A1 (en) * 2001-02-02 2002-08-08 Pfizer Inc. Treatment of diabetes mellitus using vardenafil
DE10107639A1 (de) 2001-02-15 2002-08-22 Bayer Ag 2-Alkoxyphenyl-substituierte Imidazotriazinone
ATE348618T1 (de) * 2001-05-09 2007-01-15 Bayer Healthcare Ag Neue verwendung von 2-(2-ethoxy-5-(4-methyl- piperazin-1-sulfonyl)-phenyl)-5-methyl-7-propyl 3h-imidazo(5,1-f)(1,2,4)triazin-4-on
DE10135815A1 (de) * 2001-07-23 2003-02-06 Bayer Ag Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
GB0129274D0 (en) * 2001-12-06 2002-01-23 Pfizer Ltd Novel kit
CA2478145A1 (en) * 2002-03-06 2003-09-12 Cellegy Pharmaceuticals, Inc. Formulations and methods of using nitric oxide mimetics in cancer treatment

Also Published As

Publication number Publication date
HRP20040065A2 (en) 2004-12-31
DE50213840D1 (de) 2009-10-22
US20040235838A1 (en) 2004-11-25
KR20040032865A (ko) 2004-04-17
US20080085897A1 (en) 2008-04-10
IL159840A0 (en) 2004-06-20
WO2003011262A3 (de) 2004-05-27
RU2321406C9 (ru) 2009-03-27
DE10135815A1 (de) 2003-02-06
HUP0500734A3 (en) 2005-12-28
CO5560536A2 (es) 2005-09-30
ES2330418T3 (es) 2009-12-10
JP2005504751A (ja) 2005-02-17
CN1649593A (zh) 2005-08-03
WO2003011262A2 (de) 2003-02-13
EP1733728A3 (de) 2007-03-21
HUP0500734A2 (hu) 2005-11-28
EP1474150B1 (de) 2009-09-09
US7276504B2 (en) 2007-10-02
CA2454414A1 (en) 2003-02-13
RU2321406C2 (ru) 2008-04-10
US6930108B2 (en) 2005-08-16
AU2002319296B2 (en) 2007-08-30
SK442004A3 (en) 2004-06-08
ATE442144T1 (de) 2009-09-15
EE200400056A (et) 2004-04-15
PL373392A1 (en) 2005-08-22
NZ530703A (en) 2006-06-30
EP1733728A2 (de) 2006-12-20
BG108533A (bg) 2005-02-28
MXPA04000675A (es) 2004-11-22
ECSP044956A (es) 2004-02-26
MA26128A1 (fr) 2004-04-01
CZ2004128A3 (cs) 2004-08-18
US20050234022A1 (en) 2005-10-20
EP1474150A2 (de) 2004-11-10
RU2004105265A (ru) 2005-04-20
NO20040294L (no) 2004-01-22
UA76997C2 (en) 2006-10-16

Similar Documents

Publication Publication Date Title
BR0211359A (pt) Emprego de imidazotriazinonas substituìdas por 2-alcoxifenila
BR112022002599A2 (pt) Vesícula extracelular ligada a moléculas e usos da mesma
BRPI0210941B8 (pt) produto farmacêutico contendo combinações de oxazolidinonas substituídas, seu uso, seu processo de produção, e medicamento
ATE469132T1 (de) Substituierte 5-alkinyl-pyrimidine mit neurotropher wirkung
BR0214825A (pt) Uréias de 2-aminobenzotiazóis como moduladores de adenosina
BR0009507A (pt) Derivados de ftalazina para o tratamento de doenças inflamatórias
DE60236520D1 (de) Synthese und verwendung von reagenzien für die verbesserte dna-lipofektion und/oder prodrug- und arzneimitteltherapien mit langsamer freisetzung
HN1999000124A (es) Derivados de pirazol substituido.
BRPI0410029A (pt) dihidroquinazolinas substituìdas
SV2002000357A (es) Acidos malonamicos y derivados de los mismos como ligandos de receptor tiroideo ref pc10748amag/bb
UY38766A (es) Derivados de imidazo[1,2-a]piridinilo y su uso en el tratamiento de enfermedades
CY1107735T1 (el) Φωτο-ευαισθητοποιητες
MY147864A (en) Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin
BR9913746F1 (pt) derivado de piridínio, processo para a preparação do mesmo, uso do mesmo, composição farmacêutica, processo para preparação de uma formulação parenteral, e, métodos de tratamento de um paciente diabético e de prevenção ou de tratamento de doenças causadas por diabetes e por complicações relacionadas com o envelhecimento
BR0210473A (pt) Composição compreendendo um inibidor da pde-4 e antagonista do receptor-h1 e seus usos na produção de um medicamento para o tratamento de doenças respiratórias
ES2186576B1 (es) Acido 2-hidroxioleico para utilizar como medicamento.
ATE144139T1 (de) Verwendung von phenylethanolaminen zur herstellung von medikamenten gegen augenleiden
BRPI0517972A (pt) ácido 5,6,7-triidroxiheptanóico e análogos para o tratamento de doenças oculares e doenças associadas com respostas hiperproliferativas e angiogênicas
MY174012A (en) Role of n-2-hydroxy-ethyl-piperazine-n'-2-ethane sulfonic acid (hepes) in pain control and reversal of demyelinization injury
BR0304224A (pt) Uso de pentraxina longa ptx3 para o tratamento de doenças de tumor mediado por fgf-8
BR0008394A (pt) Composição para o tratamento da psorìase
Šinkūnaitė et al. Focal neurogenic muscle hypertrophy and fasciculations in multifocal motor neuropathy
ES2289134T3 (es) Uso de estrogenos no feminizantes como agentes protectores de la retina para el tratamiento del glaucoma.
CN214970092U (zh) 一种精神科护理输液固定器
Xia et al. Clinical study of acupuncture combined with medication in the treatment of skin pruritus in maintenance hemodialysis patients

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A E 9A A NUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2108 DE 31/05/2011.